<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="331b69c5-5ad7-a90a-e063-6394a90acfd6"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use MOXIFLOXACIN OPHTHALMIC SOLUTION safely and effectively. See full prescribing information for MOXIFLOXACIN OPHTHALMIC SOLUTION.
 <br/>
      <br/>
MOXIFLOXACIN ophthalmic solution, for topical ophthalmic use
 <br/>
Initial U.S. Approval: 1999
</title>
   <effectiveTime value="20250419"/>
   <setId root="8f92f110-32d6-4d0c-a415-7a9a4cafb9b8"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="059888437"/>
            <name>Asclemed USA, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="059888437"/>
                        <name>ASCLEMED USA INC. DBA ENOVACHEM</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73607" displayName="relabel" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="76420-331" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="335a141d-c39a-eff9-e063-6294a90a3937"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250419"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="76420-331" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Moxifloxacin Hydrochloride</name>
                        <formCode code="C42986" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Moxifloxacin Hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="0832-1410" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R57ZHV85D4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="5"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="C53598599T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MOXIFLOXACIN HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="U188XYD42P" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MOXIFLOXACIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="3" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="76420-331-03" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250419"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA212616" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20210210"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="331b69c5-5ad8-a90a-e063-6394a90acfd6"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20210131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="80%" align="left" valign="top"/>
                           <col width="20%" align="left" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>Dosage and Administration (
    
       <linkHtml href="#S2">2</linkHtml>)
   
      </td>
                                 <td>6/2020</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="331b69c5-5ad9-a90a-e063-6394a90acfd6"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:</paragraph>
                  <paragraph>
                     <content styleCode="italics">Corynebacterium</content>species
 
  <footnote ID="ft2">Efficacy for this organism was studied in fewer than 10 infections.</footnote>
                     <br/>
                     <content styleCode="italics">Micrococcus luteus
  
   <footnoteRef IDREF="ft2"/>
                        <br/>  Staphylococcus aureus 
   <br/>  Staphylococcus epidermidis 
   <br/>  Staphylococcus haemolyticus 
   <br/>  Staphylococcus hominis 
   <br/>  Staphylococcus warneri
  
   <footnoteRef IDREF="ft2"/>
                        <br/>  Streptococcus pneumoniae 
   <br/>  Streptococcus viridans
 
  </content>group 
  <br/>
                     <content styleCode="italics">Acinetobacter lwoffii
  
   <footnoteRef IDREF="ft2"/>
                        <br/>  Haemophilus influenza 
   <br/>  Haemophilus parainfluenzae
  
   <footnoteRef IDREF="ft2"/>
                        <br/>  Chlamydia trachomatis
 
  </content>
                  </paragraph>
               </text>
               <effectiveTime value="20210131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Moxifloxacin ophthalmic solution is a topical fluoroquinolone anti- infective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:</paragraph>
                        <paragraph>
                           <content styleCode="italics">Corynebacterium</content>species*,
 
    <content styleCode="italics">Micrococcus luteus*, Staphylococcus aureus, Staphylococcus epidermidis</content>,
 
    <content styleCode="italics">Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus warneri*, Streptococcus pneumoniae, Streptococcus viridans</content>group,
 
    <content styleCode="italics">Acinetobacter lwoffii*, Haemophilus influenzae, Haemophilus parainfluenzae*, Chlamydia trachomatis</content>
                        </paragraph>
                        <paragraph>*Efficacy for this organism was studied in fewer than 10 infections. (
 
    <linkHtml href="#S1">1</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="331b69c5-5ada-a90a-e063-6394a90acfd6"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>
                     <content styleCode="xmChange">Instill one drop in the affected eye 3 times a day for 7 days. Moxifloxacin ophthalmic solution is for topical ophthalmic use.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20210131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Instill one drop in the affected eye 3 times a day for 7 days. (
 
    <linkHtml href="#S2">2</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="331b69c5-5adb-a90a-e063-6394a90acfd6"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Ophthalmic solution containing moxifloxacin 0.5%.</paragraph>
               </text>
               <effectiveTime value="20210131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Ophthalmic solution containing moxifloxacin 0.5%. (
 
    <linkHtml href="#S3">3</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="331b69c5-5adc-a90a-e063-6394a90acfd6"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Moxifloxacin ophthalmic solution is contraindicated in patients with a history of hypersensitivity to moxifloxacin, to other quinolones, or to any of the components in this medication.</paragraph>
               </text>
               <effectiveTime value="20210131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Moxifloxacin ophthalmic solution is contraindicated in patients with a history of hypersensitivity to moxifloxacin, to other quinolones, or to any of the components in this medication. (
 
    <linkHtml href="#S4">4</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="331b69c5-5add-a90a-e063-6394a90acfd6"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20210131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Hypersensitivity Reactions</content>: Hypersensitivity and anaphylaxis have been reported with systemic use of moxifloxacin. (
  
     <linkHtml href="#S5.1">5.1</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">Prolonged Use:</content>May result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy. (
  
     <linkHtml href="#S5.2">5.2</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">Avoid Contact Lens Wear</content>: Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis. (
  
     <linkHtml href="#S5.3">5.3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="331b69c5-5ade-a90a-e063-6394a90acfd6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>In patients receiving systemically administered quinolones, including moxifloxacin, serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported, some following the first dose. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching. If an allergic reaction to moxifloxacin occurs, discontinue use of the drug. Serious acute hypersensitivity reactions may require immediate emergency treatment. Oxygen and airway management should be administered as clinically indicated.</paragraph>
                     </text>
                     <effectiveTime value="20210131"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="331b69c5-5adf-a90a-e063-6394a90acfd6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Growth of Resistant Organisms With Prolonged Use</title>
                     <text>
                        <paragraph>As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit-lamp biomicroscopy, and, where appropriate, fluorescein staining.</paragraph>
                     </text>
                     <effectiveTime value="20210131"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="331b69c5-5ae0-a90a-e063-6394a90acfd6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Avoidance of Contact Lens Wear</title>
                     <text>
                        <paragraph>Patients should be advised not to wear contact lenses if they have signs or symptoms of bacterial conjunctivitis.</paragraph>
                     </text>
                     <effectiveTime value="20210131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="331b69c5-5ae1-a90a-e063-6394a90acfd6"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                  <paragraph>The most frequently reported ocular adverse events were conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, and tearing. These events occurred in approximately 1% to 6% of patients.</paragraph>
                  <paragraph>Non-ocular adverse events reported at a rate of 1% to 4% were fever, increased cough, infection, otitis media, pharyngitis, rash, and rhinitis.</paragraph>
               </text>
               <effectiveTime value="20210131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most frequently reported ocular adverse events were conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, and tearing. These events occurred in approximately 1% to 6% of patients. (
 
    <linkHtml href="#S6">6</linkHtml>)

   </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Upsher-Smith Laboratories, LLC at 1-855-899-9180 or FDA at 1-800-FDA-1088 or
  
     <content styleCode="underline">www.fda.gov/medwatch</content>.
 
    </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="331b69c5-5ae2-a90a-e063-6394a90acfd6"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution.
 
  <content styleCode="italics">In vitro</content>studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.

 </paragraph>
               </text>
               <effectiveTime value="20210131"/>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="331b69c5-5ae3-a90a-e063-6394a90acfd6"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20210131"/>
               <component>
                  <section ID="S8.1">
                     <id root="331b69c5-5ae4-a90a-e063-6394a90acfd6"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20210131"/>
                     <component>
                        <section>
                           <id root="331b69c5-5ae5-a90a-e063-6394a90acfd6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no adequate and well-controlled studies with moxifloxacin ophthalmic solution in pregnant women to inform any drug-associated risks.</paragraph>
                              <paragraph>Oral administration of moxifloxacin to pregnant rats and monkeys and intravenously to pregnant rabbits during the period of organogenesis did not produce adverse maternal or fetal effects at clinically relevant doses. Oral administration of moxifloxacin to pregnant rats during late gestation through lactation did not produce adverse maternal, fetal or neonatal effects at clinically relevant doses
 
  <content styleCode="italics">(see
  
   <linkHtml href="#data">Data</linkHtml>).
 
  </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20210131"/>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="331b69c5-5ae6-a90a-e063-6394a90acfd6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20210131"/>
                           <component>
                              <section>
                                 <id root="331b69c5-5ae7-a90a-e063-6394a90acfd6"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Embryo-fetal studies were conducted in pregnant rats administered with 20, 100, or 500 mg/kg/day moxifloxacin by oral gavage on Gestation Days 6 to 17, to target the period of organogenesis. Decreased fetal body weight and delayed skeletal development were observed at 500 mg/kg/day [277 times the human area under the curve (AUC) at the recommended human ophthalmic dose]. The No-Observed-Adverse-Effect-Level (NOAEL) for developmental toxicity was 100 mg/kg/day (30 times the human AUC at the recommended human ophthalmic dose).</paragraph>
                                    <paragraph>Embryo-fetal studies were conducted in pregnant rabbits administered with 2, 6.5, or 20 mg/kg/day moxifloxacin by intravenous administration on Gestation Days 6 to 20, to target the period of organogenesis. Abortions, increased incidence of fetal malformations, delayed fetal skeletal ossification, and reduced placental and fetal body weights were observed at 20 mg/kg/day (1,086 times the human AUC at the recommended human ophthalmic dose), a dose that produced maternal body weight loss and death. The NOAEL for developmental toxicity was 6.5 mg/kg/day (246 times the human AUC at the recommended human ophthalmic dose).</paragraph>
                                    <paragraph>Pregnant cynomolgus monkeys were administered moxifloxacin at doses of 10, 30, or 100 mg/kg/day by intragastric intubation between Gestation Days 20 and 50, targeting the period of organogenesis. At the maternal toxic doses of ≥ 30 mg/kg/day, increased abortion, vomiting, and diarrhea were observed. Smaller fetuses/reduced fetal body weights were observed at 100 mg/kg/day (2,864 times the human AUC at the recommended human ophthalmic dose). The NOAEL for fetal toxicity was 10 mg/kg/day (174 times the human AUC at the recommended human ophthalmic dose).</paragraph>
                                    <paragraph>In a pre- and postnatal study, rats were administered moxifloxacin by oral gavage at doses of 20, 100, and 500 mg/kg/day from Gestation Day 6 until the end of lactation. Maternal death occurred during gestation at 500 mg/kg/day. Slight increases in the duration of pregnancy, reduced pup birth weight, and decreased prenatal and neonatal survival were observed at 500 mg/kg/day (estimated 277 times the human AUC at the recommended human ophthalmic dose). The NOAEL for pre- and postnatal development was 100 mg/kg/day (estimated 30 times the human AUC at the recommended human ophthalmic dose).</paragraph>
                                 </text>
                                 <effectiveTime value="20210131"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="331b69c5-5ae8-a90a-e063-6394a90acfd6"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20210131"/>
                     <component>
                        <section>
                           <id root="331b69c5-5ae9-a90a-e063-6394a90acfd6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There is no data regarding the presence of moxifloxacin ophthalmic solution in human milk, the effects on the breastfed infants, or the effects on milk production/excretion to inform risk of moxifloxacin ophthalmic solution to an infant during lactation.</paragraph>
                              <paragraph>A study in lactating rats has shown transfer of moxifloxacin into milk following oral administration.</paragraph>
                              <paragraph>Systemic levels of moxifloxacin following topical ocular administration are low
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]
 
  </content>, and it is not known whether measurable levels of moxifloxacin would be present in maternal milk following topical ocular administration.

 </paragraph>
                              <paragraph>The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for moxifloxacin ophthalmic solution and any potential adverse effects on the breastfed child from moxifloxacin ophthalmic solution.</paragraph>
                           </text>
                           <effectiveTime value="20210131"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="331b69c5-5aea-a90a-e063-6394a90acfd6"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of moxifloxacin ophthalmic solution have been established in all ages. Use of moxifloxacin ophthalmic solution is supported by evidence from adequate and well controlled studies of moxifloxacin ophthalmic solution in adults, children, and neonates
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]
 
  </content>.

 </paragraph>
                        <paragraph>There is no evidence that the ophthalmic administration of moxifloxacin ophthalmic solution has any effect on weight bearing joints, even though oral administration of some quinolones has been shown to cause arthropathy in immature animals.</paragraph>
                     </text>
                     <effectiveTime value="20210131"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="331b69c5-5aeb-a90a-e063-6394a90acfd6"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>No overall differences in safety and effectiveness have been observed between elderly and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20210131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="331b69c5-5aec-a90a-e063-6394a90acfd6"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Moxifloxacin ophthalmic solution, USP 0.5% is a sterile solution for topical ophthalmic use. Moxifloxacin hydrochloride is an 8-methoxy fluoroquinolone anti-infective, with a diazabicyclononyl ring at the C7 position. Chemical Name: 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolol[3,4b]pyridin­6-yl]-4-oxo-3-quinolinecarboxylic acid, monohydrochloride. The molecular formula for moxifloxacin hydrochloride, USP is C
 
  <sub>21</sub>H
 
  <sub>24</sub>FN
 
  <sub>3</sub>O
 
  <sub>4</sub>∙HCl and its molecular weight is 437.9 g/mol. The chemical structure is presented below.

 </paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Moxifloxacin hydrochloride is a slightly yellow to yellow crystalline powder.</paragraph>
                  <paragraph>Each mL of moxifloxacin ophthalmic solution contains 5.45 mg moxifloxacin hydrochloride, equivalent to 5 mg moxifloxacin base. Moxifloxacin ophthalmic solution contains: Active: Moxifloxacin 0.5% (5 mg/mL); Inactives: Boric acid, purified water and sodium chloride. May also contain hydrochloric acid/sodium hydroxide to adjust pH to approximately 6.8.</paragraph>
                  <paragraph>Moxifloxacin ophthalmic solution, USP is an isotonic solution with an osmolality of approximately 290 mOsm/kg.</paragraph>
               </text>
               <effectiveTime value="20210131"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="moxifloxacin-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="331b69c5-5aed-a90a-e063-6394a90acfd6"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20210131"/>
               <component>
                  <section ID="S12.1">
                     <id root="331b69c5-5aee-a90a-e063-6394a90acfd6"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Moxifloxacin is a member of the fluoroquinolone class of anti-infective drugs
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S12.4">Microbiology (12.4)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20210131"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="331b69c5-5aef-a90a-e063-6394a90acfd6"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Plasma concentrations of moxifloxacin were measured in healthy adult male and female subjects who received bilateral topical ocular doses of moxifloxacin ophthalmic solution 3 times a day. The mean steady-state C
 
  <sub>max</sub>(2.7 ng/mL) and AUC
 
  <sub>0-00</sub>(41.9 ng∙hr/mL) values were 1,600 and 1,100 times lower than the mean C
 
  <sub>max</sub>and AUC reported after therapeutic 400 mg doses of moxifloxacin. The plasma half-life of moxifloxacin was estimated to be 13 hours.

 </paragraph>
                     </text>
                     <effectiveTime value="20210131"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.4">
                     <id root="331b69c5-5af0-a90a-e063-6394a90acfd6"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4 Microbiology</title>
                     <text>
                        <paragraph>The antibacterial action of moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.</paragraph>
                        <paragraph>The mechanism of action for quinolones, including moxifloxacin, is different from that of macrolides, aminoglycosides, or tetracyclines. Therefore, moxifloxacin may be active against pathogens that are resistant to these antibiotics and these antibiotics may be active against pathogens that are resistant to moxifloxacin. There is no cross-resistance between moxifloxacin and the aforementioned classes of antibiotics. Cross-resistance has been observed between systemic moxifloxacin and some other quinolones.</paragraph>
                        <paragraph>
                           <content styleCode="italics">In vitro</content>resistance to moxifloxacin develops via multiple-step mutations. Resistance to moxifloxacin occurs
 
  <content styleCode="italics">in vitro</content>at a general frequency of between 1.8 × 10
 
  <sup>-9</sup>to less than 1 × 10
 
  <sup>-11</sup>for gram-positive bacteria.

 </paragraph>
                        <paragraph>Moxifloxacin has been shown to be active against most strains of the following microorganisms, both
 
  <content styleCode="italics">in vitro</content>and in clinical infections as described in the Indications and Usage section:

 </paragraph>
                     </text>
                     <effectiveTime value="20210131"/>
                     <component>
                        <section>
                           <id root="331b69c5-5af1-a90a-e063-6394a90acfd6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="underline">Aerobic Gram-Positive Microorganisms</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Corynebacterium</content>species
 
  <content styleCode="italics">
                                    <footnote ID="ft3">Efficacy for this organism was studied in fewer than 10 infections.</footnote>
                                    <br/>  Micrococcus luteus
  
   <footnoteRef IDREF="ft3"/>
                                    <br/>  Staphylococcus aureus 
   <br/>  Staphylococcus epidermidis 
   <br/>  Staphylococcus haemolyticus 
   <br/>  Staphylococcus hominis 
   <br/>  Staphylococcus warneri
  
   <footnoteRef IDREF="ft3"/>
                                    <br/>  Streptococcus pneumoniae 
   <br/>  Streptococcus viridans
 
  </content>group

 </paragraph>
                           </text>
                           <effectiveTime value="20210131"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="331b69c5-5af2-a90a-e063-6394a90acfd6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="underline">Aerobic Gram-Negative Microorganisms</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Acinetobacter lwoffii</content>
                                 <footnoteRef IDREF="ft3"/>
                                 <br/>
                                 <content styleCode="italics">Haemophilus influenza 
   <br/>  Haemophilus parainfluenzae
  </content>
                                 <footnoteRef IDREF="ft3"/>
                              </paragraph>
                           </text>
                           <effectiveTime value="20210131"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="331b69c5-5af3-a90a-e063-6394a90acfd6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="underline">Other Microorganisms</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Chlamydia trachomatis</content>
                              </paragraph>
                              <paragraph>The following
 
  <content styleCode="italics">in vitro</content>data are also available,
 
  <content styleCode="bold">but their clinical significance in ophthalmic infections is unknown.</content>The safety and effectiveness of moxifloxacin ophthalmic solution in treating ophthalmological infections due to these microorganisms have not been established in adequate and well-controlled trials.

 </paragraph>
                              <paragraph>The following organisms are considered susceptible when evaluated using systemic breakpoints. However, a correlation between the
 
  <content styleCode="italics">in vitro</content>systemic breakpoint and ophthalmological efficacy has not been established. The list of organisms is provided as guidance only in assessing the potential treatment of conjunctival infections.

 </paragraph>
                              <paragraph>Moxifloxacin exhibits
 
  <content styleCode="italics">in vitro</content>minimal inhibitory concentrations (MICs) of 2 microgram/mL or less (systemic susceptible breakpoint) against most (greater than or equal to 90%) strains of the following ocular pathogens.

 </paragraph>
                           </text>
                           <effectiveTime value="20210131"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="331b69c5-5af4-a90a-e063-6394a90acfd6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="underline">Aerobic Gram-Positive Microorganisms</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Listeria monocytogenes 
   <br/>  Staphylococcus saprophyticus 
   <br/>  Streptococcus agalactiae 
   <br/>  Streptococcus mitis 
   <br/>  Streptococcus pyogenes 
   <br/>  Streptococcus
  </content>Group C, G and F

 </paragraph>
                           </text>
                           <effectiveTime value="20210131"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="331b69c5-5af5-a90a-e063-6394a90acfd6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="underline">Aerobic Gram-Negative Microorganisms</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Acinetobacter baumannii 
   <br/>  Acinetobacter calcoaceticus 
   <br/>  Citrobacter freundii 
   <br/>  Citrobacter koseri 
   <br/>  Enterobacter aerogenes 
   <br/>  Enterobacter cloacae 
   <br/>  Escherichia coli 
   <br/>  Klebsiella oxytoca 
   <br/>  Klebsiella pneumoniae 
   <br/>  Moraxella catarrhalis 
   <br/>  Morganella morganii 
   <br/>  Neisseria gonorrhoeae 
   <br/>  Proteus mirabilis 
   <br/>  Proteus vulgaris 
   <br/>  Pseudomonas stutzeri
  </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20210131"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="331b69c5-5af6-a90a-e063-6394a90acfd6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="underline">Anaerobic Microorganisms</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Clostridium perfringens 
   <br/>  Fusobacterium
  </content>species 
  <br/>
                                 <content styleCode="italics">Prevotella</content>species 
  <br/>
                                 <content styleCode="italics">Propionibacterium acnes</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20210131"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="331b69c5-5af7-a90a-e063-6394a90acfd6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="underline">Other Microorganisms</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Chlamydia pneumoniae 
   <br/>  Legionella pneumophila 
   <br/>  Mycobacterium avium 
   <br/>  Mycobacterium marinum 
   <br/>  Mycoplasma pneumoniae
  </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20210131"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="331b69c5-5af8-a90a-e063-6394a90acfd6"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20210131"/>
               <component>
                  <section ID="S13.1">
                     <id root="331b69c5-5af9-a90a-e063-6394a90acfd6"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20210131"/>
                     <component>
                        <section>
                           <id root="331b69c5-5afa-a90a-e063-6394a90acfd6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="underline">Carcinogenesis</content>
                                 </content>
                              </paragraph>
                              <paragraph>Long-term studies in animals to determine the carcinogenic potential of moxifloxacin have not been performed. However, in an accelerated study with initiators and promoters, moxifloxacin was not carcinogenic in rats following up to 38 weeks of oral dosing at 500 mg/kg/day (3,224 times the highest recommended total daily human ophthalmic dose for a 60 kg person, based on body surface area).</paragraph>
                           </text>
                           <effectiveTime value="20210131"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="331b69c5-5afb-a90a-e063-6394a90acfd6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="underline">Mutagenesis</content>
                                 </content>
                              </paragraph>
                              <paragraph>Moxifloxacin was not mutagenic in four bacterial strains used in the Ames
 
  <content styleCode="italics">Salmonella</content>reversion assay. As with other quinolones, the positive response observed with moxifloxacin in strain TA 102 using the same assay may be due to the inhibition of DNA gyrase. Moxifloxacin was not mutagenic in the CHO/HGPRT mammalian cell gene mutation assay. An equivocal result was obtained in the same assay when V79 cells were used. Moxifloxacin was clastogenic in the V79 chromosome aberration assay, but it did not induce unscheduled DNA synthesis in cultured rat hepatocytes. There was no evidence of genotoxicity
 
  <content styleCode="italics">in vivo</content>in a micronucleus test or a dominant lethal test in mice.

 </paragraph>
                           </text>
                           <effectiveTime value="20210131"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="331b69c5-5afc-a90a-e063-6394a90acfd6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="underline">Impairment of Fertility</content>
                                 </content>
                              </paragraph>
                              <paragraph>Moxifloxacin had no effect on fertility in male and female rats at oral doses as high as 500 mg/kg/day, approximately 3,224 times the highest recommended total daily human ophthalmic dose, based on body surface area. At 500 mg/kg/day orally, there were slight effects on sperm morphology (head-tail separation) in male rats and on the estrous cycle in female rats.</paragraph>
                           </text>
                           <effectiveTime value="20210131"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="331b69c5-5afd-a90a-e063-6394a90acfd6"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>In two randomized, double-masked, multicenter, controlled clinical trials in which patients were dosed 3 times a day for 4 days, moxifloxacin ophthalmic solution produced clinical cures on Day 5 to 6 in 66% to 69% of patients treated for bacterial conjunctivitis. Microbiological success rates for the eradication of baseline pathogens ranged from 84% to 94%.</paragraph>
                  <paragraph>In a randomized, double-masked, multicenter, parallel-group clinical trial of pediatric patients with bacterial conjunctivitis between birth and 31 days of age, patients were dosed with moxifloxacin ophthalmic or another anti-infective agent. Clinical outcomes for the trial demonstrated a clinical cure rate of 80% at Day 9 and a microbiological eradication success rate of 92% at Day 9.</paragraph>
                  <paragraph>Please note that microbiologic eradication does not always correlate with clinical outcome in anti-infective trials.</paragraph>
               </text>
               <effectiveTime value="20210131"/>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="331b69c5-5afe-a90a-e063-6394a90acfd6"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Moxifloxacin hydrochloride ophthalmic solution, USP is supplied as a sterile ophthalmic solution in a low-density polyethylene dropper tip bottle with a tan polypropylene cap closure. Tamper evidence is provided with a band around the neck area of the package.</paragraph>
                  <paragraph>3 mL in a 5 mL bottle – NDC 76420-331-03 (relabeled from NDC 0832-1410-03)</paragraph>
               </text>
               <effectiveTime value="20250419"/>
               <component>
                  <section>
                     <id root="331b69c5-5aff-a90a-e063-6394a90acfd6"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Storage: Store at 2°C to 25°C (36°F to 77°F).</paragraph>
                     </text>
                     <effectiveTime value="20210131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="331b69c5-5b00-a90a-e063-6394a90acfd6"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <effectiveTime value="20210131"/>
               <component>
                  <section>
                     <id root="331b69c5-5b01-a90a-e063-6394a90acfd6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Avoid Contamination of the Product</content>
                        </paragraph>
                        <paragraph>Advise patients not to touch the dropper tip to any surface to avoid contaminating the contents.</paragraph>
                     </text>
                     <effectiveTime value="20210131"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="331b69c5-5b02-a90a-e063-6394a90acfd6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Avoid Contact Lens Wear</content>
                        </paragraph>
                        <paragraph>Advise patients not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20210131"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="331b69c5-5b03-a90a-e063-6394a90acfd6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hypersensitivity Reactions</content>
                        </paragraph>
                        <paragraph>Systemically administered quinolones including moxifloxacin have been associated with hypersensitivity reactions, even following a single dose. Instruct patients to discontinue use immediately and contact their physician at the first sign of a rash or allergic reaction
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20210131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="331b69c5-5b04-a90a-e063-6394a90acfd6"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Relabeled by:</content>
                  </paragraph>
                  <paragraph>Enovachem PHARMACEUTICALS</paragraph>
                  <paragraph>Torrance, CA 90501</paragraph>
               </text>
               <effectiveTime value="20250419"/>
            </section>
         </component>
         <component>
            <section ID="id_link_332bb7b8-0623-a589-e063-6294a90a3f35">
               <id root="332bb7b8-0622-a589-e063-6294a90a3f35"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_332bb786-640c-182e-e063-6394a90a460a"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250419"/>
               <component>
                  <observationMedia ID="img_332bb786-640c-182e-e063-6394a90a460a">
                     <text>label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>